Association between vascular access failure and the use of specific drugs: The Dialysis Outcomes and Practice Patterns Study (DOPPS)

American Journal of Kidney Diseases

Volumn 40, Issue 6, 2002, Pages 1255-1263

  Saran, Rajiv ^a,b,c   Dykstra, Dawn M ^a,b,c   Wolfe, Robert A ^a,b,c   Gillespie, Brenda ^a,b,c   Held, Philip J ^a,b,c   Young, Eric W ^a,b,c  

^a Univ Ren Res and Educ Assoc   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

Arteriovenous (AV) fistula; Arteriovenous (AV) graft; Drugs; Hemodialysis (HD); Outcomes research; Vascular access

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANGINA PECTORIS AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; COUMARIN ANTICOAGULANT; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETODOLAC; FLURBIPROFEN; HEPARIN DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDOMETACIN; IRBESARTAN; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; KETOPROFEN; KETOROLAC; LOSARTAN; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PENTOXIFYLLINE; PIROXICAM; SULINDAC; UNINDEXED DRUG; VALSARTAN;

ADULT; AGED; AORTA ANEURYSM; ARTERIOVENOUS SHUNT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DRUG EFFECT; DRUG INDICATION; DRUG USE; FEMALE; GRAFT SURVIVAL; HEMODIALYSIS; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATION; OUTCOMES RESEARCH; PROSPECTIVE STUDY; SURVIVAL; TREATMENT FAILURE; TREATMENT INDICATION; VALVULAR HEART DISEASE; VASCULAR ACCESS; VASCULAR PATENCY;

EID: 0036897094     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2002.36895     Document Type: Article

References (32)

1. Woods JD, Port FK: The impact of vascular access for hemodialysis on patient morbidity and mortality. Nephrol Dial Transplant 12:657-659, 1997
2. National Kidney Foundation: K/DOQI clinical practice guidelines for vascular access, 2000. Am J Kidney Dis 37:S137-S181, 2001 (suppl 1)
3. Roy-Chaudhury P, Kelly BS, Miller MA, et al: Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 59:2325-2334, 2001
4. Weiss MF, Scivittaro V, Anderson JM: Oxidative stress and increased expression of growth factors in lesions of failed hemodialysis access. Am J Kidney Dis 37:970-980, 2001
5. Himmelfarb J: Pharmacologic prevention of vascular access stenosis. Curr Opin Nephrol Hypertens 8:569-572, 1999
6. Sukhatme VP: Vascular access stenosis: Prospects for prevention and therapy. Kidney Int 49:1161-1174, 1996
7. Goodkin DA, Mapes DL, Held PJ: The Dialysis Outcomes and Practice Patterns Study (DOPPS): How can we improve the care of hemodialysis patients? Semin Dial 14:157-159, 2001
8. Young EW, Goodkin DA, Mapes DL, et al: The Dialysis Outcomes and Practice Patterns Study: An international hemodialysis study. Kidney Int 57:S74-S81, 2000 (suppl 74)
9. US Renal Data System: USRDS 1999 Annual Data Report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 1999
10. SAS Institute Inc: SAS/STAT® Users Guide, Version 8. Cary, NC, SAS Institute Inc, 1999
11. Cox DR: Regression models and life tables (with discussion). J R Stat Soc 34:187-220, 1972
12. Klein JP, Moeschberger ML: Survival Analysis Techniques for Censored and Truncated Data. New York, NY, Springer, 1997, p 417
13. Wolfe RA: Observational studies are just as effective as clinical trials. Blood Purif 8:323-326, 2000
14. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM: Anti-platelet therapy in graft thrombosis: Results of a prospective, randomized, double-blind study. Kidney Int 45: 1477-1483, 1994
15. Domoto DT, Bauman JE, Joist JH: Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. Thromb Res 62:737-743, 1991
16. al-Momen AK, Huraib SO: Low-dose danazol for vascular access and dialyzer thrombosis in hemodialysis patients. Haemostasis 22:12-16, 1992
17. Radmilovic A, Boric Z, Naumovic T, Stamenkovic M, Musikic P: Shunt thrombosis prevention in hemodialysis patients-A double-blind, randomized study: Pentoxifylline vs placebo. Angiology 38:499-506, 1987
18. Diskin CJ, Thomas CE, Zellner CP, Lock S, Tanja J: Fish oil to prevent intimal hyperplasia and access thrombosis. Nephron 55:445-447, 1990
19. Schmitz PG, McCloud LK, Reikes ST, Leonard CL, Gellens ME: Prophylaxis of hemodialysis graft thrombosis with fish oil: Double-blind, randomized, prospective trial. J Am Soc Nephrol 13:184-190, 2000
20. Hakim R, Himmelfarb J: Hemodialysis access failure: A call to action. Kidney Int 54:1029-1040, 1998
21. Ross R: Atherosclerosis: A defense mechanism gone awry. Am J Pathol 143:987-1002, 1993
22. Gradzki R, Dhingra RK, Port FK, Roys E, Weitzel WF, Messana JM: Use of ACE inhibitors is associated with prolonged survival of arteriovenous grafts. Am J Kidney Dis 38:1240-1244, 2001
23. Harvey R, Bredenberg CE, Couper L, Himmelfarb J: Aspirin enhances platelet derived growth factor-induced vascular smooth muscle cells. J Vasc Surg 25:689-695, 1997
24. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308:81-106, 1994
25. Himmelfarb J, Couper L: Dipyridamole inhibits PDGF and bFGF-induced vascular smooth muscle proliferation. Kidney Int 52:1671-1677, 1997
26. Nakao J, Ito H, Chang WC, Koshiara Y, Moruta S: Aortic smooth muscle migration caused by platelet derived growth factor is mediated by lipoxygenase products of arachidonic acid. Biochem Biophys Res Commun 112:866-871, 1983
27. Taber TE, Maikranz PS, Haag BW, et al: Maintenance of adequate hemodialysis access. Prevention of neointimal hyperplasia. ASAIO J 41:842-846, 1995
28. Huang P, Hawthorne WJ, Peng A, Angeli GL, Medbury HJ, Fletcher JP: Calcium channel antagonist verapamil inhibits neointimal formation and enhances apoptosis in a vascular graft model. Am J Surg 181:492-498, 2001
29. Brauner R, Laks H, Drinkwater DC Jr, et al: Controlled periadventitial administration of verapamil inhibits neointimal smooth muscle cell proliferation and ameliorates vasomotor abnormalities in experimental vein bypass grafts. J Thorac Cardiovasc Surg 114:53-63, 1997
30. LeSar CJ, Merrick HW, Smith MR: Thrombotic complications resulting from hypercoagulable states in chronic hemodialysis vascular access. J Am Coll Surg 189:73-79, 1999
31. Pisoni RL, Young EW, Dykstra DM, et al: Vascular access use in Europe and the United States: Results from the DOPPS. Kidney Int 61:305-316, 2002
32. Libby P: Current concepts of the pathogenesis of acute coronary syndromes. Circulation 104:365-372, 2001